SCYNEXIS, Inc. provides pharmaceutical products. The Company discovers, develops, and distributes intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans. SCYNEXIS serves customers in the United States.

Current Report (Form 8-K | Period ending 2024-11-06)

424B5 | Prospectus

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

SCYNEXIS (SCYX US)

Current Report (Form 8-K | Period ending 2024-11-06)

424B5 | Prospectus

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-09-10)

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)